Country: Austria
Language: English
Source: HMA (Heads of Medicines Agencies)
ramipril 1.25 mg
Intervet Deutschland GmbH
QC09AA05
Tablet
ramipril
Dogs Non Food
2010-06-08
I.B.1. SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Vasotop P 1.25mg, tablet for dogs and cats. In DK, IE and NO, the name of the veterinary medicinal product is Vasotop 1.25 mg tablet. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substance 1 tablet of Vasotop P 1.25mg contains: 1.25 mg Ramipril as active ingredient. For a full list of excipients, see section 6.1 3. PHARMACEUTICAL FORM Beige oblong tablet with score line on both sides. Embossing : Upper side with 1.25 on both sides of the score line – Lower side : V on both sides of the score line The tablets can be divided into equal halves. 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Dogs and cats. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES Dogs For treatment of congestive heart failure (according to New York Heart Association (NYHA) classification grade II, III & IV) caused by valvular insufficiency due to chronic degenerative valvular heart disease (endocardiosis) or cardiomyopathy, with or without adjunct therapy with the diuretic furosemide and / or the cardiac glycosides digoxin or methyldigoxin. Class Clinical signs II Fatigue shortness of breath, coughing etc. become evident when ordinary exercise is exceeded. Ascites may appear at this stage. III Comfortable at rest, but exercise capacity is minimal IV No capacity for exercise. Disabling clinical signs are present even at rest. In patients treated concurrently with the product and furosemide the dose of the diuretic can be reduced to achieve the same diureti Read the complete document